인간 간 모델 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Human Liver Model Market size is expected to reach USD 7.32 Billion in 2034 from USD 2.18 Billion (2025) growing at a CAGR of 14.38% during 2026-2034.

The global human liver model market is gaining traction as demand for advanced preclinical testing, drug discovery, and personalized medicine intensifies. Traditional 2D cultures and animal models face limitations in replicating human liver physiology, driving interest in 3D bioprinted, organ-on-chip, and stem cell-derived liver models. These technologies enable more accurate simulation of drug metabolism, toxicity, and disease progression, improving translational success rates.

Pharmaceutical companies are adopting human liver models to accelerate drug pipelines, minimize clinical trial failures, and comply with stringent regulatory requirements for safety evaluation. Research institutes are leveraging liver-on-chip platforms to study conditions such as nonalcoholic fatty liver disease (NAFLD), hepatitis, and fibrosis in controlled environments. Moreover, bioprinting advances and scalable culture systems are facilitating commercial deployment of highly reproducible liver tissues.

In the future, integration of human liver models with AI-driven predictive analytics, high-throughput screening, and multi-organ platforms will reshape biomedical research. As precision medicine advances, patient-derived liver models will allow individualized therapy testing, paving the way for customized treatment protocols. With growing convergence of biotechnology, tissue engineering, and computational biology, the market is poised to revolutionize drug development and disease modeling.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• 2D Models (Cell lines, Primary Cells)
• 3D Models (Liver on Chip, Organoids, Spheroids, Others)

By Application

• ADME Studies
• Toxicology Testing
• Disease Modelling
• Others

By End Use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

COMPANIES PROFILED

• ATCC, Merck KGaA, AcceGen, ZenBio Inc, Organovo Holdings Inc, BioIVT, InSphero, Emulate Inc, Mimetas, CN Bio Innovations Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN LIVER MODEL MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. 2D Models (Cell lines, Primary Cells) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. 3D Models (Liver on Chip, Organoids, Spheroids, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN LIVER MODEL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. ADME Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Toxicology Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Disease Modelling Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN LIVER MODEL MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN LIVER MODEL MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Application
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Application
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Application
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Application
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Application
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN LIVER MODEL INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 ATCC
  • 9.2.2 Merck KGaA
  • 9.2.3 AcceGen
  • 9.2.4 ZenBio Inc
  • 9.2.5 Organovo Holdings Inc
  • 9.2.6 BioIVT
  • 9.2.7 InSphero
  • 9.2.8 Emulate Inc
  • 9.2.9 Mimetas
  • 9.2.10 CN Bio Innovations Ltd